MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jgo.2016.007906

Медицинская библиотека · Journal of global oncology · 2017

Variation in Adherence Measures to Imatinib Therapy.

Yanamandra Uday, Malhotra Pankaj, Sahu K K, Sushma Yanamandra, Saini Neha, Chauhan Pooja, Gill Jasmeen, Rikhi Deepika, Khadwal Alka, Prakash Gaurav, Lad Deepesh, Suri Vikas, Kumari Savita, Varma Neelam, Varma Subhash

СтатьяНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

PURPOSE: The introduction of tyrosine kinase inhibitors has transformed the care of patients with chronic myeloid leukemia, with survival approaching that of healthy individuals. Current-day challenges in chronic myeloid leukemia care include adherence to tyrosine kinase inhibitor therapy. We studied adherence from resource-constrained settings and tried to analyze the factors responsible for nonadherence in these individuals. We also correlated adherence to current molecular status.

PATIENTS AND

METHODS

This was a single-center, cross-sectional, observational study from north India. It consisted of a questionnaire-based survey in which a one-to-one interview technique was used by trained nursing staff administering the Modified Morisky Adherence Scale (MMAS-9) questionnaire. Adherence was also measured on the basis of physician's assessment. JMP 13.0.0 was used for statistical analysis.

RESULTS

A total of 333 patients with a median age of 42 years were included in the study. The median BCR-ABL/ABL ratio (IS) was 0.175 (0.0 to 98.0). The mean MMAS-9 score was 11 ± 2. Adherence was seen in 54.95% on the basis of MMAS-9, whereas physician's assessment reported adherence in 90.39% of patients. Using the χ2 test, no relationship was found between the two assessment techniques. There was a significant relationship between major molecular response status and adherence by physician's assessment and MMAS-9 ( P < .001). Bivariate analysis by logistic fit showed a good relation between the MMAS-9 score and the BCR-ABL/ABL ratio (IS), χ2 (1,220) = 135.45 ( P < .001). On multivariate analysis, enrolment in the Novartis Oncology Access program (a patient assistance program) was significantly associated with adherence ( P = .012).

CONCLUSION

This study highlights the lack of adherence in real-world settings and the various factors responsible. Such studies are important from a public health services perspective in various settings around the world because they may lead to corrective action being taken at the institutional level.

Для цитирования: Yanamandra Uday, Malhotra Pankaj, Sahu K K, Sushma Yanamandra, Saini Neha, Chauhan Pooja, Gill Jasmeen, Rikhi Deepika, Khadwal Alka, Prakash Gaurav, Lad Deepesh, Suri Vikas, Kumari Savita, Varma Neelam, Varma Subhash. Variation in Adherence Measures to Imatinib Therapy.. Journal of global oncology. 2017. DOI: 10.1200/jgo.2016.007906.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.